Inflammatory activation and left ventricular mass in essential hypertension

American Journal of Hypertension

Volumn 22, Issue 4, 2009, Pages 444-450

  Roselló Lletí, Esther ^a   Rivera, Miguel ^a   Martínez Dolz, Luís ^a   González Juanatey, Jose R ^b   Cortés, Raquel ^a   Jordán, Alejandro ^c   Morillas, Pedro ^d   Lauwers, Catheline ^e   Calabuig, Jose R ^a   Antorrena, Isabel ^f   De Rivas, Beatriz ^g   Portolés, Manuel ^a   Bertomeu, Vicente ^d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Hospital General Universitario   (Spain)

^d HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^e Hospital Francesc Borja   (Spain)

^f HOSPITAL MARINA BAIXA   (Spain)

^g ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 62849105036     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.369     Document Type: Article

References (33)

1. Liu Y, Liu T, McCarron RM, Spatz M, Feuerstein G, Hallenbeck JM, Sirén AL. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 1996; 270:H2125-H2131.
2. González-Clemente JM, Giménez-Pérez G, Richart C, Broch M, Caixàs A, Megia A, Giménez-Palop O, Simón I, Mauricio D, Vendrell J. The tumor necrosis factor (TNF)-α system is activated in accordance with pulse pressure in normotensive subjects with type 1 diabetes mellitus. Eur J Endocrinol 2005; 153:687-691.
3. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38:399-403.
4. Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T. Proinflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 2001; 31:31-36.
5. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, Park JR, Kim SW. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16:429-433.
6. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 2001; 103:947-953.
7. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
8. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38:1829-1835.
9. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 1998; 12:58-66.
10. Leibowitz D, Planer D, Ben-Ivgi F, Weiss A, Bursztyn M. Tumor necrosis factor and interleukin-6 levels in hypertensive patients with and without left ventricular hypertrophy. Blood Press 2005; 14:21-24.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
12. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
13. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
14. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32:865-875.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sanchs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
17. Cortés R, Otero MR, Morillas P, Roselló-Lletí E, Grigorian L, Martínez-Dolz L, de Burgos FG, Calabuig JR, Soria F, Lozano T, Portolés M, Bertomeu V. Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels. Am J Hypertens 2008; 21:820-825.
18. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, Watanabe S, Morita N, Nakao K, Fujiwara H. Marked expression plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 28:1234-1242.
19. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, Mukoyama M, Nakao K, Imura H, Sasayama S. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88:372-380.
20. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94:1543-1553.
21. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100:999-1008.
22. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599-2610.
23. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB; Strong Heart Study. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003; 26:2764-2769.
24. Sciarretta S, Ferrucci A, Ciavarella GM, De Paolis P, Venturelli V, Tocci G, De Biase L, Rubattu S, Volpe M. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007; 20:784-791.
25. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95:1247-1252.
26. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovkaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005; 111:863-870.
27. Lavie CJ, Milani RV, Ventura HO, Messerli FH. Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol 2006; 98:1396-1399.
28. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006; 58:81-88.
29. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46:735-739.
30. Ohtsuka T, Hamada M, Hiasa G, Sasakii O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K. Effect of β-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37:412-417.
31. Imaizumi T, Nejima J, Kiuchi K, Takeda S, Seino Y, Tanaka K, Takano T. Dynamics and source of endothelin-1 and interleukin-6 following coronary reperfusion in patients with acute myocardial infarction. J Nippon Med Sch 2007; 74:131-47.
32. Radaelli A, Loardi C, Cazzaniga M, Balestri G, Decarlini C, Cerrito MG, Cusa EN, Guerra L, Garducci S, Santo D, Menicanti L, Paolini G, Azzellino A, Lavitrano ML, Mancia G, Ferrari AU. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler Thromb Vasc Biol 2007; 27:2750-2755.
33. Mayosi BM, Keavney B, Kardos A, Davies CH, Ratcliffe PJ, Farrall M, Watkins H. Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur Heart J 2002; 23:1963-1971.